Rifaximin

CHEMBL1617 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

785.9 g/mol

LogP

6.9

Phase

4

A minimally absorbed antibiotic that stays primarily in the gastrointestinal tract, used to treat traveler's diarrhea, reduce recurrent hepatic encephalopathy, and manage irritable bowel syndrome with diarrhea. Because very little enters the bloodstream, it has fewer systemic side effects than other antibiotics.

Молекулярная масса

785,9000 g/mol

LogP

6,90

TPSA

198,00 Å²

Правило пяти Липинского

Не соответствует

Терапевтические области

Non-Small Cell Lung Cancer Alzheimer's Disease Parkinson's Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Hypertension Breast Cancer HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C

InChI

InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1

Molecular Formula

C43H51N3O11

HBD / HBA

5 / 12

Вращаемые Связи

3

Тяжёлые Атомы

57

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A minimally absorbed antibiotic that stays primarily in the gastrointestinal tract, used to treat traveler's diarrhea, reduce recurrent hepatic encephalopathy, and manage irritable bowel syndrome with diarrhea. Because very little enters the bloodstream, it has fewer systemic side effects than other antibiotics.

Yes, Rifaximin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1617. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6436173. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Rifaximin на PillFYI

Структура

Краткие Данные

Формула: C43H51N3O11
Синонимы: 1

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.